Avoro Capital Advisors LLC has acquired 3,111,111 shares of Celcuity Inc. for $99.74 per share, making it a new addition to their biotechnology-focused portfolio. This acquisition represents 3.86% of Avoro’s portfolio and reflects confidence in Celcuity’s oncology developments despite the latter’s low GF Score and profitability/growth rankings. Celcuity is a clinical-stage biotech company with a lead therapeutic candidate, gedatolisib, for advanced breast cancer.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuit
Avoro Capital Advisors LLC has acquired 3,111,111 shares of Celcuity Inc. for $99.74 per share, making it a new addition to their biotechnology-focused portfolio. This acquisition represents 3.86% of Avoro’s portfolio and reflects confidence in Celcuity’s oncology developments despite the latter’s low GF Score and profitability/growth rankings. Celcuity is a clinical-stage biotech company with a lead therapeutic candidate, gedatolisib, for advanced breast cancer.